AbbVie reported adjusted diluted EPS of $3.65 for Q2 2026, surpassing analyst expectations of $3.60, and achieved revenues of $16.99 billion, exceeding forecasts of $16.78 billion. Strong growth in its Immunology and Neuroscience segments drove this performance, with blockbuster drugs Skyrizi and Rinvoq generating $8.79 billion in sales. The company also announced plans to acquire Apogee Therapeutics to expand its immunology pipeline and raised its full-year 2026 adjusted EPS guidance to $13.87–$14.07, reflecting confidence in continued growth and innovation.
AbbVie reported strong second-quarter results with net revenues of $16.99 billion, up 10.2% year-over-year, driven by growth in its immunology and neuroscience portfolios. Adjusted diluted EPS rose 22.9% to $3.65, despite a $0.17 per share impact fro...
Allergan Aesthetics celebrates the 20th anniversary of JUVÉDERM's FDA approval with its fourth annual JUVÉDERM Day on August 19, 2026. The event offers Allē loyalty program members exclusive deals including buy-one-get-one (BOGO) $75 gift cards and d...
The European Commission has approved RINVOQ (upadacitinib) for treating non-segmental vitiligo (NSV) in adults and adolescents aged 12 and older. This marks the first systemic medication authorized in the EU for NSV, the most common form of vitiligo,...
The European Commission has approved RINVOQ (upadacitinib) for treating severe alopecia areata in adults and adolescents 12 years and older, based on Phase 3 clinical trials demonstrating significant scalp hair regrowth and improvements in eyebrows a...
US stock futures point to a strong start with Dow Jones up 1.1%, S&P 500 up 0.9%, and Nasdaq up 1.5%, driven by a sharp 6.3% drop in oil prices following a pause in US-Iran military actions. Although no official ceasefire is declared, Iran has agreed...
